| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2007;115:1738-1746.)
© 2007 American Heart Association, Inc.
Congenital Heart Disease |
From the Department of Cardiac Electrophysiology (D.J.A., M.J.E., S.C.S., P.M.K., R.J.S.), St Bartholomews Hospital; Adult Congenital Heart Program (M.A.G., M.J.M., J.A.T.), The Royal Brompton Hospital; and Grown Up Congenital Heart Unit (S.C., F.W., J.E.D.) and Department of Cardiac Electrophysiology (M.D.L.), The Heart Hospital, London, United Kingdom.
Correspondence to Dr Richard Schilling, MD, FRCP, Cardiology Research Department, Dominion House, St Bartholomews Hospital, London, EC1A 7BE, United Kingdom. E-mail r.schilling{at}qmul.ac.uk
Received April 19, 2006; accepted December 27, 2006.
| Abstract |
|---|
|
|
|---|
Methods and Results Mapping was performed in 26 patients aged 26.8±8.9 years, 18.7±4.4 years after Fontan surgery. The area and site of abnormal endocardium defined by electroanatomic mapping (bipolar contact electrogram <0.5 mV) were compared with those defined by noncontact mapping during sinus rhythm and by dynamic substrate mapping. Contact and reconstructed unipolar electrograms at a known distance from the multielectrode array, recorded by the noncontact system simultaneously at 452 endocardial sites, were compared for morphological cross correlation, timing difference, and amplitude. Mapping of arrhythmias was performed with both systems when possible. The median patient abnormal endocardium as defined by electroanatomic mapping covered 38.0% (range 16.7% to 97.8%) of the right atrial surface area, as opposed to 60.9% (range 21.3% to 98.5%) defined by noncontact mapping during sinus rhythm and 11.9% (range 0.4% to 67.3%) by dynamic substrate mapping. A significant decrease in electrogram cross correlation (P=0.003), timing (P=0.012), and amplitude (P=0.003) of reconstructed electrograms, but not of contact electrograms (P=0.742), was seen at endocardial sites >40 mm from the multielectrode array. Successful arrhythmia mapping by electroanatomic versus noncontact mapping was superior in 15 patients (58%), the same in 6 (23%), and inferior in 5 (19%; P=0.044).
Conclusions Electroanatomic mapping is the superior modality for arrhythmia mapping late after the Fontan procedure. Noncontact mapping is limited by a significant reduction in reconstructed electrogram correlation, timing, and amplitude >40 mm from the multielectrode array and cannot accurately define areas of scar and low-voltage endocardium.
Key Words: mapping arrhythmia electrophysiology ablation Fontan procedure
| Introduction |
|---|
|
|
|---|
Editorial p 1698
Clinical Perspective p 1746
| Methods |
|---|
|
|
|---|
1 antiarrhythmic medication, including amiodarone (n=17). Accurate knowledge of the underlying anatomy and prior surgical intervention was confirmed by reference to operation notes. Anatomic obstruction and atrial thrombus were excluded by cardiac magnetic resonance and/or transesophageal echocardiography, and oral anticoagulation was used in all patients. Antiarrhythmic drugs were stopped
5 half-lives before the study (amiodarone
2 months) unless sustained arrhythmia had been documented on current medication. The local ethics committee approved the study, and patients gave written consent before the procedure.
Electrophysiology Study
Studies were performed with simultaneous noncontact (EnSite; St. Jude Medical, St. Paul, Minn) and electroanatomic (CARTO; Biosense Webster, Diamond Bar, Calif) mapping systems. Contact catheter data were recorded simultaneously on a conventional electrophysiology system (LabSystem, Bard Electrophysiology, Murray Hill, NJ). Heparin boluses were used to maintain an activated clotting time >300 seconds. Sinus rhythm (SR) was recorded by both noncontact and electroanatomic systems at the beginning of the case, before any intervention. In the event of sustained tachycardia at the start of the study, SR maps were acquired after arrhythmia termination by radiofrequency catheter ablation. In those with no spontaneous sinus node activity, a surrogate "sinus" map was recorded during atrial pacing from the nearest area of endocardium to the position of the sinoatrial node where consistent capture could be achieved. We attempted to map all induced arrhythmias with both systems, and intravenous adenosine was used to facilitate noncontact mapping by transient elimination of ventricular activation.
Noncontact Mapping
The noncontact mapping system has been described in detail previously.5 Briefly, a noncontact MEA mounted onto a 7.5-mL balloon detects raw data from the endocardial surface, which are relayed to a computer workstation via an amplifier. The MEA was placed over a 0.035-in J-wire and advanced from the left femoral vein to either the superior vena cava or left pulmonary artery. The noncontact system was used to locate a Navistar mapping catheter (Biosense Webster) with respect to the MEA to create a computer model of the endocardium ("virtual endocardium"). A ring electrode positioned on the proximal shaft of the MEA was used both to record a contact unipolar EGM from the distal electrode of the mapping catheter and as a reference for the reconstructed unipolar EGM.
Electroanatomic Mapping
Electroanatomic mapping was performed with the quadripolar Navistar mapping catheter, which enabled color-coded atrial activation referenced to a stable bipolar catheter to be superimposed on a 3D geometry. Bipolar signals were filtered at 30 to 400 Hz and displayed at 200 mm/s. Local endocardial activation was taken as the first steep deflection away from the baseline.
Offline Analysis
Chamber Size and Distance From MEA
The RA surface area was automatically calculated by the electroanatomic system and by the noncontact system with a customized Excel template (Microsoft Corp, Redmond, Wash). To determine the RA surface area >40 mm from the MEA, in each patient, we recorded the distance of 256 equally distributed endocardial points from the MEA.
Determination of Abnormal Endocardium
The identification of scar tissue and abnormal endocardium with the electroanatomic mapping system has been validated previously against pathological13,14 and echocardiographic14 findings in animal models. On the basis of the results of previous clinical studies,1517 abnormal endocardium was defined as the sum of (1) scar (no identifiable EGM or bipolar amplitude
0.05 mV15,16) and (2) low-voltage endocardium with bipolar contact amplitude of
0.5 mV.16,17
Bipolar voltage maps were created in which the color scale indicated local peak-to-peak EGM amplitude; scar was depicted by gray, normal endocardium by purple, and low-voltage endocardium by colors red to purple (Figure 1). A surface-area calculation tool was used to determine the area of abnormal endocardium, expressed as a fraction of the RA surface area.
|
To identify abnormal endocardium with the noncontact mapping system, we used previously described techniques that suggest this is the area where local EGM amplitude is <30% of the peak negative (<30%PN) EGM on static isopotential maps.10 During SR, this area was termed SR <30%PN. In an attempt to minimize "far-field" oversensing, we used dynamic substrate mapping (DSM), a technique that involves additional sequential pacing at 800 ms from multiple sites within the RA, to identify the area consistently <30%PN (ie, the intersection of all areas <30%PN defined during SR and pacing). This area was termed DSM <30%PN (Figure 1). During pacing, a blanking period was applied to eliminate stimulus artifact. The areas of SR <30%PN and DSM <30%PN were defined with a surface-area measurement tool incorporated in the noncontact mapping system and expressed as a fraction of the total RA area. In addition, the areas encompassed by <10%PN, <20%PN, and <50%PN were also defined during both SR and DSM. Using anatomic landmarks such as the caval vein orifices, RA to pulmonary artery connection, and coronary sinus os, we were able to determine an approximate measure of geometric concordance of the location of abnormal endocardium determined by the 2 mapping systems, defined as follows: good (>75% concordance between the 2 areas), moderate (50% to 75%), and poor (<50%).
Reconstructed EGM Validation
To assess the efficacy of the noncontact mapping system, we compared reconstructed unipolar EGMs from the endocardial surface with a simultaneously acquired contact unipolar EGM sampled from the distal pole of the mapping catheter tip at the identical location. The 2 EGMs were compared as described below (Figure 2).
|
Morphological Cross Correlation
The morphology of the reconstructed and contact EGM was compared with a validated18,19 template-matching algorithm that produces a cross correlation [C(k)] that indicates the morphological similarity, where X and Y are the corresponding amplitudes of all points constituting the reconstructed and contact EGMs, respectively: equation
|
|
Timing Difference
The time shift (k) over a window of ±50 ms required to create the best morphological correlation between the 2 EGMs was taken as the timing difference.
Amplitude
Because the morphological correlation may be insensitive to changes in amplitude,20 contact and reconstructed EGMs were additionally expressed as the root mean squared of all positive and negative components of the EGM. To compensate for the effect of multiple measurements per patient, a mean value was calculated for EGM morphology, timing, and amplitude in each patient for endocardial sites <40 and >40 mm from the MEA.
Detection of Arrhythmia
Electroanatomic mapping and noncontact mapping were used to map all encountered arrhythmias, and subsequent analysis of those arrhythmias recorded successfully was performed offline. Macroreentrant arrhythmias were defined as an organized atrial tachycardia with stable cycle length, EGM morphology, and consistent pattern of atrial activation. Macroreentry arrhythmias were only accepted as successfully mapped if a complete loop of atrial activation could be demonstrated on isopotential or activation maps, corroborated by noncontact and contact EGMs, and >90% of the tachycardia cycle length could be accounted for within the RA.21 Where appropriate, the contribution of fixed and/or functional conduction block to arrhythmia mechanism was assessed. Conduction block was defined as double potentials separated by an isoelectric or low-amplitude interval of >50 ms,16 conduction delay of >50 ms in adjacent contact electrodes, or acute wavefront cessation. Fixed conduction block was present under all circumstances, whereas functional block was deemed to be a factor of atrial cycle length or direction of activation. Focal arrhythmia was defined as an organized atrial tachycardia with stable cycle length, ECG morphology, and consistent pattern of centrifugal activation from a focal source.
To compensate for the fact that multiple arrhythmias may be recorded in any 1 patient, the efficacy of the 2 mapping systems to identify arrhythmias was calculated for the total number of patients and by dividing patients into groups according to different mechanisms. In any given patient, if electroanatomic mapping identified a greater number of arrhythmias than noncontact mapping, this was deemed to be the superior technique irrespective of the number of arrhythmias, and vice versa. If both systems identified the same number of arrhythmias, they were deemed equally effective/ineffective. For each of the 5 different arrhythmia mechanisms, the superiority of either electroanatomic or noncontact mapping was determined in an identical fashion. Patients with more than 1 identified arrhythmia mechanism (eg, functional and focal) were included in each appropriate group.
Radiofrequency Ablation
Irrigated radiofrequency ablation (RFA; 30 mL/min; 45°C/50 W) was used in all cases, and pace mapping and/or entrainment pacing was used to identify candidate sites for RFA when necessary. Success was defined in each patient as termination during RFA in the absence of atrial ectopy and/or noninducibility by rapid burst atrial pacing or programmed atrial stimulation of all targeted arrhythmia mechanisms.
Statistical Analysis
Continuous variables were assessed for normal distribution by Kolmogorov-Smirnov analysis. Normally distributed data were expressed as mean±SD and nonnormally distributed data as median (range). Comparisons between noncontact and electroanatomic voltage characteristics were assessed by the Bland-Altman technique. The distribution of EGM data <40 and >40 mm from the MEA in each patient was compared with the Wilcoxon signed rank test. The McNemar test with a continuity correction was used to determine the superiority of either electroanatomic mapping or noncontact mapping to detect arrhythmia in each patient. Ablation success was assessed per patient with the Fisher exact test. Statistical significance was taken as P<0.05. Data were analyzed with StatView (SAS Software, Cary, NC) and Microsoft Excel WinStat (Microsoft, Redmond, Wash).
All authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
| Results |
|---|
|
|
|---|
Determination of Abnormal Endocardium
Electroanatomic mapping of SR was not possible in 2 patients owing to sinoatrial node disease, and noncontact mapping was not possible in 1. Comparisons between scar and noncontact mapping could therefore be made in 25 patients, and comparisons between abnormal endocardium and noncontact mapping could be performed in 23. DSM <30%PN was performed in 11 patients at a mean of 3.8 pacing points per patient. The median patient abnormal endocardium as defined by electroanatomic mapping covered 38.0% (16.7% to 97.8%) of the RA surface area (scar 15.07% [1.89% to 56.15%] and low-voltage endocardium 25.25% [7.38% to 55.11%]) as opposed to 60.9% (21.3% to 98.5%) defined by noncontact mapping during SR and 11.9% (0.4% to 67.3%) by DSM. Comparative analysis between electroanatomic and noncontact mapping to define abnormal endocardium is depicted in Table 1 and Figure 3. For <10%PN and <20%PN, either SR or 1 or more pacing points failed to identify any region with reconstructed EGM voltage of <10% or 20% of the peak negative voltage. Because of this, a valid comparison could not be made between the area of abnormal endocardium defined by DSM <10%PN and DSM <20%PN with that defined by DSM <30%PN in 9 of 11 and 4 of 11 patients, respectively. The degree of geometric concordance between the 2 systems was assessed between the nearest comparison (electroanatomic scar versus DSM <30%PN), which was good in only 2 cases and poor in the remaining 9 (Figure 1).
|
|
Reconstructed EGM Validation
Analysis was performed on 452 paired EGMs in 12 patients. The distance of the sample sites from the MEA was 43 (17 to 79) mm, of which 231 (51.1%) were >40 mm from the MEA. A significant reduction in morphological cross correlation (P=0.003), timing difference (P=0.012), and reconstructed EGM amplitude (P=0.003) was seen with increasing distance from the MEA, but no difference was seen in the amplitude of contact EGMs (P=0.742; Figure 4A through 4D). Additionally, an increase was seen in the ratio of mean contact to reconstructed EGM amplitude that indicated a fall in reconstructed versus contact EGM amplitude at distances >40 mm from the MEA (Figure 4E).
|
Detection of Arrhythmia
We encountered 43 RA arrhythmias, 3 left atrial arrhythmias, and 1 of undetermined mechanism. Left atrial arrhythmias were identified by an inability to entrain the arrhythmia from the RA endocardium. Of the RA arrhythmias, 33 were macroreentrant, 9 were focal, and 1 was atrioventricular nodal reentry tachycardia. For the purposes of analysis, additional sources of centrifugal RA activation (3 left atrial arrhythmias and 1 atrioventricular nodal reentry tachycardia) were classified as focal. Macroreentrant arrhythmias were further classified into 4 groups as follows: (1) fixedwavefront rotation perpendicular to the vertical axis of the RA, dependent on fixed conduction block on the posterolateral wall of the RA at the position of the crista terminalis (n=7); (2) functionalwavefront rotation perpendicular to the vertical axis of the RA, dependent on fixed and functional conduction block on the posterolateral wall of the RA at the position of the crista terminalis (n=8); (3) isthmusperiannular reentry via the cavotricuspid isthmus (n=5); and (4) scarscar-related reentry in which the wavefront rotates around scar or sites of fixed conduction block remote from anatomic obstacles (n=13).
Electroanatomic mapping identified a significantly greater proportion of all arrhythmias (P=0.044), but by individual mechanisms, only scar-related macroreentry was identified significantly more often by electroanatomic mapping (P=0.044). Results are summarized in Table 2. In none of the 4 patients with functional conduction block supporting the arrhythmia in whom DSM was performed did DSM <30% identify the site of functional conduction block. All 9 arrhythmias for which noncontact mapping alone was successful were not sufficiently sustained to permit electroanatomic mapping.
|
Radiofrequency Ablation
RFA was performed in 24 patients, targeting 41 of 43 RA arrhythmias, 33 during tachycardia and 8 during SR. Ablation was not performed in 2 patients with clinical left atrial arrhythmias and 2 RA arrhythmias owing to focal His bundle origin and inability to reinduce a focal arrhythmia terminated with adenosine. Success (elimination of all targeted arrhythmias excluding atrial fibrillation) was achieved in 21 (87.5%) of 24 patients. No difference existed in RFA success in patients in whom electroanatomic mapping was superior (11 of 14% [78%; 95% confidence interval 50% to 95%]), noncontact mapping was superior (5 of 5 [100%; 95% confidence interval 48% to 100%]), or both systems were equal (5 of 5 [100%; 95% confidence interval 48% to 100%]; P=0.55).
| Discussion |
|---|
|
|
|---|
Determination of Abnormal Endocardium
Electroanatomic bipolar voltage maps using previously reported amplitude criteria1517 demonstrated that after the Fontan procedure, a significant proportion of the RA surface area is covered by abnormal endocardium (scar or low-voltage endocardium <0.5 mV). Although this has been documented previously,13 this is the first time it has been accurately quantified in patients with congenital heart disease. For all comparisons between electroanatomic mapping and noncontact mapping using the previously defined figure of <30%PN,10 the corroboration between the 2 systems was poor, as judged by the bias and wide levels of agreement (Table 1; Figure 3) and supported by the finding of poor geometric concordance between scar defined by electroanatomic mapping and DSM <30%PN in 9 of 11 patients. Identification of abnormal endocardium with noncontact mapping therefore appears to be fundamentally limited by the decrease in reconstructed EGM amplitude with increasing distance of the MEA from the endocardium. Additionally, the use of both <10%PN and <20%PN is further limited by the finding that in some patients (with clear evidence of abnormal endocardium on electroanatomic contact maps), the area of abnormal endocardium is 0 cm2.
Bipolar contact EGMs remain the most commonly used and clinically accepted method to define areas of abnormal endocardium9,1317,22 and arrhythmia mapping in the context of congenital13,9 and structural15,16 heart disease. Bipolar EGMs have been found to be superior to unipolar EGMs in the detection of infarcted myocardium when validated against pathological and intracardiac echocardiographic findings,14 as well as in the determination of scar in congenital heart disease,9 and at present, this is the benchmark against which noncontact mapping can be judged. The area <30%PN proposed by Higa et al10 is based on the mean reduction of contact unipolar EGMs in infarcted myocardium,13,14,22 although we have shown that endocardium <30%PN is due to increasing distance from the MEA, which may in part explain the discrepancy between the 2 mapping systems. Given the frequent association of scar and dilated chambers in both congenital810 and structural16,18 heart disease, this technique may be misleading if used to define low-voltage endocardium in patients with enlarged atria.
Two previous studies have assessed the ability of DSM to identify scar in experimental models of myocardial infarction, with conflicting results. In line with the findings of the present study, Thiagalingam et al11 found neither reconstructed EGMs nor DSM reliably identified ventricular scar. Conversely, Jacobson et al12 found DSM to be a reliable method for the localization of infarcted myocardium compared with pathological findings, although the technique used to create an infarct of predictable location produced a dense transmural lesion, which may have little resemblance to the substrate produced by myocardial ischemia in humans or by surgical intervention and chronic stretch, as in the Fontan procedure.
Reconstructed EGM Validation
The results of the present study support the findings of previous investigators58 that at distances >40 mm between the endocardium and MEA, the accuracy of reconstructed EGM correlation and timing falls significantly (Figure 4). That such a significant proportion of the RA endocardium is >40 mm from the MEA suggests that EGM reconstruction in large areas of endocardium will be poor in the majority of patients after the Fontan procedure.
Detection of Arrhythmia and RFA
Electroanatomic mapping was the superior modality in arrhythmia identification in a significantly greater number of patients in all arrhythmias encountered. Additionally, the electroanatomic system was superior in the identification of scar-based macroreentry arrhythmia, in keeping with our finding that defining endocardium that has <30% voltage of the peak negative voltage with noncontact mapping does not accurately detect either scar or abnormal endocardium. Although the difference was not statistically significant, electroanatomic mapping identified all periannular arrhythmias, as opposed to only 1 identified by the noncontact system. This is not surprising given the natural position adopted by the MEA at the posterolateral aspect of the chamber, which is anatomically distant from the cavotricuspid isthmus. Similarly, noncontact mapping identified more arrhythmias that were dependent on functional conduction block at the crista terminalis, many of which were not sufficiently sustained to permit sequential contact mapping. No difference existed in RFA success between arrhythmias identified by either mapping modality, which suggests that when either mapping system does define an arrhythmia mechanism, this is clinically relevant, and the use of these maps to guide RFA is effective.
Limitations of the Study
At present, no system exists that would allow direct comparison between the anatomic location of scar and DSM <30%PN, and the degree of concordance was based purely on visual impression with empirical values considered to be of relevance to the clinical electrophysiologist. The advent of image integration to both electroanatomic and noncontact mapping systems may facilitate this process. Contact between the catheter and endocardium was assessed only by fluoroscopy and operator opinion as opposed to catheter impedance, which may have overestimated the areas of abnormal endocardium defined by electroanatomic mapping. The parameters used to define scar and abnormal endocardium are based on previous clinical studies, and as far as we are aware, they have not been validated by histological findings.
Conclusions
Electroanatomic mapping is the superior modality for arrhythmia mapping late after the Fontan procedure. Conversely, because large areas of RA endocardium are >40 mm from the MEA, the utility of noncontact mapping is limited by a significant reduction in reconstructed EGM correlation, timing, and amplitude. Additionally, noncontact mapping cannot accurately define areas of scar and low-voltage endocardium.
| Acknowledgments |
|---|
Drs Abrams and Earley were funded by grants from The British Heart Foundation. Dr Kistler is the recipient of the Neil Hamilton Fairley Fellowship from the National Health and Medical Research Council of Australia and National Heart Foundation. Professor Deanfield is the British Heart Foundation Vandervell Chair of Congenital Heart Disease. Dr Schilling was the Principle Investigator and Professors Deanfield and Gatzoulis and Drs Sporton and Cullen were coinvestigators of this study, which was funded by a project grant from the British Heart Foundation.
Disclosures
Drs Abrams and Schilling are members of the Speakers Bureau for St. Jude Medical. Dr Schilling is a member of the Scientific Advisory Board of Biosense Webster. The remaining authors report no conflicts.
| References |
|---|
|
|
|---|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |